Abstract:Arrhythmia and cardiac hypertrophy are two very common cardiovascular diseases that can lead to heart failure and even sudden death, thus presenting a serious threat to human life and health. According to global statistics, nearly one million people per year die from arrhythmia, cardiac hypertrophy and other associated cardiovascular diseases. Hence, there is an urgent need to find new treatment targets and to develop new intervention measures. Recently, mitochondrial dysfunction has been examined in relation to heart disease with a view to lowering the incidence of arrhythmia and cardiac hypertrophy. The heart is the body's largest energy consuming organ, turning over about 20 kg of adenosine triphosphate (ATP) per day in the mitochondria. Mitochondrial oxidative phosphorylation (OXPHOS) produces up to 90% of the ATP needed by cardiac muscle cells for contraction and relaxation. Dysfunction of heart mitochondria can therefore induce arrhythmia, cardiac hypertrophy and other cardiovascular diseases. Mitochondrial DNA (mtDNA) mutations cause disorders in OXPHOS and defects in the synthesis of muscle contraction proteins. These lead to insufficient production of secondary ATP, increased metabolic requirements for ATP by the myocardium, and the accumulation of reactive oxygen species (ROS). The resulting damage to myocardial cells eventually induces arrhythmia and cardiac hypertrophy. Mitochondrial damage decreases the efficiency of energy production, which further increases the production of ROS. The accumulation of ROS causes mitochondrial damage and eventually leads to a vicious cycle of mitochondrial damage and low efficiency of mitochondrial energy production. In this review, the mechanism underlying the development of arrhythmia and cardiac hypertrophy is described in relation to mitochondrial energy supply, oxidative stress, mtDNA mutation and Mitochondrial dynamics. Targeted therapy for arrhythmia and cardiac hypertrophy induced by mitochondrial dysfunction is also discussed in terms of its potential clinical value. These strategies should improve our understanding of mitochondrial biology and the pathogenesis of arrhythmia and cardiac hypertrophy. They may also identify novel strategies for targeting mitochondria in the treatment of these diseases.

A review for the correlation between optic atrophy 1-dependent mitochondrial fusion and cardiovascular disorders

Deregulation of Mitochondrial Fusion and Fission in Neurodegenerative Diseases

Mitochondria-associated membrane-modulated Ca<SUP>2+</SUP> transfer: A potential treatment target in cardiac ischemia reperfusion injury and heart failure

Molecular regulation of mitochondrial dynamics in cardiac disease

Mitochondrial Fusion and Fission in Neuronal Death Induced by Cerebral Ischemia-Reperfusion and Its Clinical Application: A Mini-Review

Mitochondrial Dysfunction: A Roadmap for Understanding and Tackling Cardiovascular Aging.

Novel insights into the involvement of mitochondrial fission/fusion in heart failure: From molecular mechanisms to targeted therapies

The role of mitochondrial dynamics in disease

The Role of Mitochondrial Fusion and Fission in the Process of Cardiac Oxidative Stress.

OPA1, a molecular regulator of dilated cardiomyopathy

Mitochondrial dynamics and cell death in heart failure

Mitochondrial Dynamics and Mitophagy in Cardiometabolic Disease

Mitochondrial Dysfunction in Arrhythmia and Cardiac Hypertrophy

Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease

Mitochondrial Dynamics: Pathogenesis and Therapeutic Targets of Vascular Diseases

Mitochondrial dysfunction and mitochondrial therapies in heart failure

From Pathophysiological Mechanisms to Therapeutic Opportunities

Pathological Roles of Mitochondrial Oxidative Stress and Mitochondrial Dynamics in Cardiac Microvascular Ischemia/Reperfusion Injury

Mitochondrial dynamics and Mitochondrial autophagy: Molecular Structure, Orchestrating Mechanism and Related Disorders

Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy